Use of inhibitors of the renin-angiotensin system

Details Use of inhibitors of the renin-angiotensin system Use of inhibitors of the renin-angiotensin system

2011-08-23

2011-08-23

Hui, San-Ming (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

08003679

ABSTRACT:
Inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia, such as stroke.

REFERENCES:
patent: 5049553 (1991-09-01), Sudilovsky
patent: 5151432 (1992-09-01), Vincent et al.
patent: 5246957 (1993-09-01), Cozzi et al.
patent: 5374643 (1994-12-01), Atwal et al.
patent: 5468757 (1995-11-01), Jakubowski et al.
patent: 5538991 (1996-07-01), Ashton et al.
patent: 5550118 (1996-08-01), Jakubowski et al.
patent: 5559135 (1996-09-01), Ashton et al.
patent: 5591762 (1997-01-01), Hauel et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5604236 (1997-02-01), Jakubowski et al.
patent: 5846989 (1998-12-01), Bonnert et al.
patent: 5846990 (1998-12-01), Murugesan et al.
patent: 5952305 (1999-09-01), Pfeffer et al.
patent: 6103732 (2000-08-01), Amberg et al.
patent: 6139847 (2000-10-01), Chobanian et al.
patent: 6197505 (2001-03-01), Norberg et al.
patent: 6258032 (2001-07-01), Hammesfahr
patent: 6335451 (2002-01-01), Kleemann et al.
patent: 6420412 (2002-07-01), Palepu et al.
patent: 6448248 (2002-09-01), Amberg et al.
patent: 6670367 (2003-12-01), Amberg et al.
patent: 7368469 (2008-05-01), Schölkens et al.
patent: 2004/0122096 (2004-06-01), Lang et al.
patent: 44 20 102 (1994-06-01), None
patent: 0 482 498 (1991-10-01), None
patent: 0459136 (1991-12-01), None
patent: 0 474 438 (1992-03-01), None
patent: 0 488 059 (1992-06-01), None
patent: 0 702 012 (1996-03-01), None
patent: 2 241 890 (1991-09-01), None
patent: WO 92/10188 (1992-06-01), None
patent: WO 93/18794 (1993-09-01), None
patent: WO 97/13513 (1997-04-01), None
patent: WO 97/21436 (1997-06-01), None
patent: WO 97/38981 (1997-10-01), None
patent: WO 98/11066 (1998-03-01), None
patent: WO 98/19690 (1998-05-01), None
patent: WO 98/33780 (1998-08-01), None
patent: WO 98/55453 (1998-12-01), None
MRC trial of treatment of mild hypertension: principal results, BMJ, 1985;291:97-104.
Wood and Hewer, Journal of Public Health Medicine, 1996;18(4):423-431.
McAlister et al., Can. J. Cardiol., 1996;12(9):822-828.
Philips et al., Arch. Intern. Med., 1992; 152:938-945.
SHEP Cooperative Research Group, JAMA, 1991;265(24):3255-3264.
Strandgaard, J Hypertens Suppl, 1996;14(3):S23-27.
Wienen et al., Br. J. Pharmacol., 1993;110:245-252.
Shimizu, K., et al., “Effects of Enalaprilat on Sympathetic Activity and Metabolism of Exercising Muscles in Rabbit, ” Clin. Exp. Pharmacol. Physiol. (1993) 20(5), 369-372.
Campbell, D.J., “Tissue Renin-Angiotensin System: Sites of Angiotensin Formation,” J. Cardiovasc. Pharmacol. (1987) 10(Suppl. 7), S1-S8.
Coats, A., “Interruption of the Progression of Heart Failure: Are ACE Inhibitors the Solution?” Cardiology (1996) 87 (Suppl. 1), 11-15.
Fuller, N.J., et al., “Assessment of the Composition of Major Body Regions by Dual-energy X-ray Absorptiometry (DEXA), with Special reference to Limb Muscle Mass,” Clinical Physiology (1992) 12, 253-266.
Cox, D.R., “Regression Models and Life-Tables,” J. Royal Statistical Society (1972) N34, 187-220.
Munzel, T., et al., “Are Alterations of Skeletal Muscle Ultrastructure in Patients with Heart Failure Reversible Under Treatment with ACE-inhibitors?” Herz (1993) 18(Suppl. 1), 400-405.
Zhang, X., et al., “ACE Inhibitors Promote Nitric Oxide Accumulation to Modulate Myocardial Oxygen Consumption,” Circulation (1997) 95(1) 14-16 (not eligible as prior art under U.S. law).
Mazess, R., et al., “Performance Evaluation of Dual=Energy X-Ray Bone Densitometer,” Calcif. Tissue Int., (1989) 44, 228-232.
O'Dell, S.D., et al., “Rapid Methods for Population-scale Analysis for Gene Polymorphisms: The ACE Gene as an Example,” Br. Heart J., (1995) 73, 368-371.
Shanmugam, V., et al., “Mistyping ACE Heterozygotes,” PCR Methods and Applications, (1993) 3, 120-121.
Cambien, F., et al., “Deletion Polymorphism in the Gene for Angiotensin-Converting Enzyme is a Potent Risk Factor for Myocardial Infarction,” Nature (1992) 359, 641-644.
Committee for Proprietary Medicinal Products, “Points to consider on Clinical Investigation of Medicinal Products for the Treatment of Acute Stroke,” The European Agency for the Evaluation of Medicinal Products (2001) 1-7. (not eligible as prior art under U.S. Law).
Ranadive, S.A., et al., “Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (ACE) Inhibitors,” Pharmaceutical Research, Sep. 1992, vol. 9 No. 11, p. 1480-1486.
Nadeau, S.E., “Stroke”, Medical Clinics of North America, Nov. 1989, vol. 73, No. 6, p. 1351-1369.
J. A. Staesson, et al., “Response to Antihypertensive Therapy in Older Patients With Sustained and Nonsustained Systolic Hypertension,” Circulation, p. 1139-1144, Sep. 5, 2000. (not eligible as prior art under U.S. Law).
J. Schrader, et al., “The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors,” Stroke, 2003, 39, 1699-1703.
Ferrario, C., “The Role of Angiotensin Antagonism in Stroke Prevention in Patients with Hypertension: Focus on Losartan,” Current Medical Research and Opinions, vol. 20, No. 11, (2004) 1797-1804 (not eligible as prior art under U.S. Law).
Kjeldsen, S.E., et al., “Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients with Isolated Systolic Hypertension and Left Ventricular Hypertrophy,” JAMA, vol. 288, No. 12, (2002) 1491-1498 (not eligible as prior art under U.S. Law).
Messerli, F. H., “The LIFE Study: The Straw that Should Break the Camel's Back,” European Heart Journal, (2003) 24, 487-489. (not eligible as prior art under U.S. Law).
Messerli, F. H., et al., “Do Thiazide Diuretics Confer Specific Protection Against Strokes?” Arch Intern Med. (2003) 163, 2557-2560. (not eligible as prior art under U.S. Law).
Lees, K.R., et al., “Blood Pressure Control After Acute Stroke,” J Hypertens Suppl. (Dec. 1996) 14(6) S35-38. (abstract only) (not eligible as prior art under U.S. Law).
Psaty, B.M., et al., “Health Outcomes Associated with Antihypertensive Therapies Used as First-line Agents. A Systematic Review and Meta-analysis,” JAMA (1997) 277(9) 739-745. (abstract only) (not eligible as prior art under U.S. Law).
Whitlock, G., et al., “Blood Pressure Lowering for the Prevention of Cognitive Decline in Patients with Cerebrovascular Disease. PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study,” Clin Exp Hypertens., (1997) 19(5-6), 843-855 (abstract only) (not eligible as prior art under U.S. Law).
Committee for Proprietary Medicinal Products, “Points to Consider on Clinical Investigation of Medicinal Products for the Treatment of Acute Stroke,” The European Agency for the Evaluation of Medicinal Products, (2001)1-7. (not eligible as prior art under U.S. Law).
PROGRESS Collaborative Group, “Randomized Trial of a Perindopril-Based Blood-Pressure-Lowering Regimen Among 6105 Individuals with Previous Stroke or Transient Ischaemic Attack,” The Lancet, (2001) 358, 1033-1041. (not eligible as prior art under U.S. Law).
Fournier, A., et al., “Stroke Prevention and Antihypertensive Treatment: May Angiotensin Receptor Type I Antagonist (AT1RA) be More Protective than Angiontensin-converting Enzyme Inhibitor (ACEI)?” Jahrgang (2000) 29, S. 545-554. (not eligible as prior art under U.S. Law).
Fournier, A., et al., “Captopril Prevention Project—What Shall We Do About Captopril and the Risk of Stroke?” Nephrol Dial Transplant (2000) 15:2-5. (not eligible as prior art under U.S. Law).
Genes, N., et al., “Comparative Lipophilicity of Trandolapril and Other ACE-Inhibitors,” Therople, (1995) 50: 131-136 (in French, abstract in English).
Hansson, L., et al., “Effect of Angiotensin-converting-enzyme Inhibition Compared with Conventional Therapy on Ca

Affiliated with

Also associated with

Rating

Use of inhibitors of the renin-angiotensin system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of inhibitors of the renin-angiotensin system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of the renin-angiotensin system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2794124